1. Kellermayer R. Translational readthrough induction of pathogenic nonsense mutations. Eur J Met Genet. 2006;49(6):445–50.
2. Mendell JT, Dietz HC. When the message goes awry: disease-producing mutations that influence mRNA content and performance. Cell. 2001;107(4):411–4.
3. PTC Therapeutics Inc. PTC therapeutics receives orphan drug designation for PTC124 for the treatment of cystic fibrosis [media release]. 2004. http://www.ptcbio.com .
4. PTC Therapeutics Inc. European Medicines Agency (EMEA) Grants PTC therapeutics orphan drug designation for PTC124 for the treatment of duchenne muscular dystrophy and cystic fibrosis [media release]. 2005. http://www.ptcbio.com .
5. PTC Therapeutics Inc. FDA’s office of orphan products development awards PTC therapeutics a grant to support clinical development of PTC124 for the treatment of nonsense-mutation-mediated cystic fibrosis [media release]. 2005. http://www.ptcbio.com .